We are live on
!
Find out more
KCA
KVP Capital Advisors Portfolio holdings
AUM
$136M
This Fund
S&P 500
This Quarter
Est. Return
+25.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$2.34M
(+1.7%)
Cap. Flow
-$18.6M
Cap. Flow
% of AUM
-13.67%
Top 10 Holdings %
Top 10 Hldgs %
57.41%
Holding
38
New
6
Increased
2
Reduced
2
Closed
3
Avg Time Held
1.4
quarters
Top 10 Avg Time Held
1.1
quarters
Top 20 Avg Time Held
1.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$5.26M |
| 2 |
ArriVent BioPharma
AVBP
|
+$3.01M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$2.31M |
| 4 |
Design Therapeutics
DSGN
|
+$2.31M |
| 5 |
Artiva Biotherapeutics
ARTV
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$23.2M |
| 2 |
Axsome Therapeutics
AXSM
|
+$5.25M |
| 3 |
Revolution Medicines
RVMD
|
+$3.91M |
| 4 |
Travere Therapeutics
TVTX
|
+$2.31M |
| 5 |
Soleno Therapeutics
SLNO
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Praxis Precision Medicines
PRAX
$7.02B
| $14.4M | 10.54% |
42,900
| – | – |
2025 Q4
2 quarters
|
|
2
Whitehawk Therapeutics
WHWK
$193M
| $9.92M | 7.28% |
2,165,997
| – | – |
2025 Q4
2 quarters
|
|
3
Erasca
ERAS
$5.41B
| $8.34M | 6.12% |
455,000
+115,000
| +34% | +$1.64M |
2026 Q1
1 quarter
|
|
4
Trevi Therapeutics
TRVI
$1.84B
| $7.72M | 5.67% |
414,000
| – | – |
2025 Q4
2 quarters
|
|
5
Sutro Biopharma
STRO
$220M
| $7.52M | 5.52% |
226,575
| – | – |
2026 Q1
1 quarter
|
|
6
Tango Therapeutics
TNGX
$4.08B
| $7.2M | 5.28% |
230,264
| – | – |
2026 Q1
1 quarter
|
|
7
MBX Biosciences
MBX
$2.51B
| $6.71M | 4.92% |
121,524
| – | – |
2025 Q4
2 quarters
|
|
8
Protagonist Therapeutics
PTGX
$9.37B
| $6.5M | 4.77% |
53,000
| – | – |
2025 Q4
2 quarters
|
|
9
Edgewise Therapeutics
EWTX
$4.18B
| $5.4M | 3.97% |
133,000
| – | – |
2025 Q4
2 quarters
|
|
|
10
Tandem Diabetes Care
TNDM
$1.14B
| $4.54M | 3.33% |
+301,000
| New | +$5.26M |
2026 Q2
0 quarters
|
|
11
Disc Medicine
IRON
$2.32B
| $4.26M | 3.13% |
58,250
| – | – |
2025 Q4
2 quarters
|
|
12
Savara
SVRA
$994M
| $3.73M | 2.74% |
605,280
| – | – |
2025 Q4
2 quarters
|
|
|
13
ArriVent BioPharma
AVBP
$812M
| $3.54M | 2.6% |
+102,000
| New | +$3.01M |
2026 Q2
0 quarters
|
|
14
Insmed
INSM
$21.5B
| $3.04M | 2.23% |
28,497
| – | – |
2025 Q4
2 quarters
|
|
15
Achieve Life Sciences
ACHV
$728M
| $3.02M | 2.22% |
462,355
| – | – |
2025 Q4
2 quarters
|
|
16
IDEAYA Biosciences
IDYA
$3.48B
| $2.97M | 2.18% |
79,700
| – | – |
2026 Q1
1 quarter
|
|
17
Ocular Therapeutix
OCUL
$1.66B
| $2.95M | 2.16% |
300,000
| – | – |
2026 Q1
1 quarter
|
|
|
18
Axsome Therapeutics
AXSM
$8.7B
| $2.94M | 2.16% |
12,000
-24,200
| -67% | -$5.25M |
2025 Q4
2 quarters
|
|
|
19
Design Therapeutics
DSGN
$683M
| $2.68M | 1.96% |
+185,000
| New | +$2.31M |
2026 Q2
0 quarters
|
|
20
United Therapeutics
UTHR
$23.6B
| $2.57M | 1.89% |
4,750
| – | – |
2025 Q4
2 quarters
|
|
21
Scholar Rock
SRRK
$5.11B
| $2.48M | 1.82% |
45,000
| – | – |
2025 Q4
2 quarters
|
|
22
Immix Biopharma
IMMX
$767M
| $2.38M | 1.74% |
230,423
| – | – |
2025 Q4
2 quarters
|
|
23
Viridian Therapeutics
VRDN
$2.07B
| $2.3M | 1.69% |
125,000
| – | – |
2026 Q1
1 quarter
|
|
|
24
Mineralys Therapeutics
MLYS
$1.97B
| $2.27M | 1.67% |
+84,168
| New | +$2.31M |
2026 Q2
0 quarters
|
|
25
Bright Minds Biosciences
DRUG
$533M
| $2.23M | 1.64% |
31,813
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
RC
TH
WFA
SB
II
FEM
SCM
VSCP
KVP Capital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, KVP Capital Advisors held 38 positions worth $136M, up 1.7% from $134M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
KVP Capital Advisors withdrew a net $18.6M in Q2 2026, closing 3 positions and reducing 2 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $23.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, KVP Capital Advisors opened a new position in Tandem Diabetes Care worth $4.54M.
- KVP Capital Advisors's largest Q2 2026 buy was Tandem Diabetes Care: 301,000 shares worth $4.54M.
- KVP Capital Advisors added most to Erasca in Q2 2026, an estimated $1.64M increase.
- KVP Capital Advisors's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.25M.
- KVP Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $23.2M.
- KVP Capital Advisors's ten largest holdings make up 57% of its $136M portfolio in Q2 2026.
- KVP Capital Advisors opened 6 new positions and closed 3 in Q2 2026.
- KVP Capital Advisors's portfolio value rose 1.7% quarter-over-quarter to $136M.
Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.